Back

X-linked adrenoleukodystrophy patient fibroblast-iPSC-derived astrocytes reveal phenotype-specific metabolic, inflammatory, and microRNA alterations

PARASAR, P.; Kaur, N.; Poisson, L.; Singh, J.

2022-09-10 neuroscience
10.1101/2022.09.09.507263 bioRxiv
Show abstract

X-linked adrenoleukodystrophy (X-ALD) is an inherited progressive metabolic disorder caused by pathogenic variants in the ABCD1 gene, which leads to accumulation of very long chain fatty acids in body fluids and tissues including brain and spinal cord. In the absence of a clear genotype-phenotype correlation the molecular mechanisms of the severe cerebral adrenoleukodystrophy (cALD) and the milder adrenomyeloneuropathy (AMN) phenotypes remain unknown. Given our previous evidence of role of astrocytes in the neuroinflammatory response in X-ALD we investigated the metabolic and molecular profiles of astrocytes derived from induced pluripotent stem cells (iPSC). The iPSCs were in turn generated from skin fibroblasts from healthy controls and patients with AMN or cALD. AMN and cALD astrocytes exhibited lack of ABCD1 and accumulation of very long chain fatty acids, a hallmark of X-ALD disease. Further, cALD astrocytes harbor significantly higher phosphorylation of STAT3, increased Toll-like receptor expression and higher chemokine and cytokine expression. In this first report of miRNA sequencing in X-ALD astrocytes, we observed that miR-9 expression was associated with increasing disease severity phenotype. CRISPR-Cas9 knock-in of ABCD1ABCD1 gene expression differentially affected the expression of key molecular, metabolic and microRNA targets in AMN and cALD astrocytes. Extensive characterization of the AMN and cALD iPSC-derived astrocyte model demonstrates critical aspects of X-ALD inflammatory disease in response to ABCD1ABCD1 mutation and can be further utilized for exploring the contribution of astrocytes to differential inflammatory response in cALD.

Matching journals

The top 12 journals account for 50% of the predicted probability mass.

1
Human Molecular Genetics
130 papers in training set
Top 0.2%
9.4%
2
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
25 papers in training set
Top 0.1%
8.6%
3
Disease Models & Mechanisms
119 papers in training set
Top 0.2%
6.5%
4
Neurobiology of Disease
134 papers in training set
Top 1.0%
5.0%
5
Scientific Reports
3102 papers in training set
Top 22%
5.0%
6
International Journal of Molecular Sciences
453 papers in training set
Top 3%
3.1%
7
PLOS ONE
4510 papers in training set
Top 42%
3.1%
8
Cells
232 papers in training set
Top 0.9%
2.9%
9
Brain
154 papers in training set
Top 2%
2.7%
10
Frontiers in Cell and Developmental Biology
218 papers in training set
Top 3%
1.9%
11
Translational Psychiatry
219 papers in training set
Top 3%
1.5%
12
Orphanet Journal of Rare Diseases
18 papers in training set
Top 0.3%
1.5%
50% of probability mass above
13
Movement Disorders
62 papers in training set
Top 0.8%
1.3%
14
Aging
69 papers in training set
Top 2%
1.3%
15
eLife
5422 papers in training set
Top 48%
1.3%
16
Open Biology
95 papers in training set
Top 1%
1.3%
17
Glia
74 papers in training set
Top 0.3%
1.3%
18
The American Journal of Human Genetics
206 papers in training set
Top 3%
1.3%
19
Annals of Neurology
57 papers in training set
Top 1%
1.3%
20
EMBO Molecular Medicine
85 papers in training set
Top 3%
1.1%
21
Fluids and Barriers of the CNS
21 papers in training set
Top 0.3%
0.9%
22
Frontiers in Molecular Neuroscience
43 papers in training set
Top 0.6%
0.9%
23
Frontiers in Neuroscience
223 papers in training set
Top 6%
0.9%
24
BMC Medical Genomics
36 papers in training set
Top 1.0%
0.9%
25
iScience
1063 papers in training set
Top 28%
0.8%
26
The Journal of Clinical Endocrinology & Metabolism
35 papers in training set
Top 1%
0.8%
27
Frontiers in Genetics
197 papers in training set
Top 9%
0.8%
28
Advanced Science
249 papers in training set
Top 18%
0.8%
29
Biochemical and Biophysical Research Communications
78 papers in training set
Top 2%
0.8%
30
Journal of Cerebral Blood Flow & Metabolism
43 papers in training set
Top 0.6%
0.8%